Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Corban v. Sarepta Therapeutics, Inc. et al
Case Number:
1:14-cv-10201
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
Companies
Sectors & Industries:
-
April 01, 2015
Sarepta Therapeutics Securities Class Action Gets The Boot
A Massachusetts federal judge on Tuesday tossed a proposed putative securities class action accusing Sarepta Therapeutics Inc. of misleading investors over the chances of its muscular dystrophy drug eteplirsen hitting the market, saying that the biopharma company couched its optimistic statements with proper disclosures.
-
January 28, 2014
Sarepta Accused Of Misleading Investors On MD Drug
A Sarepta Pharmaceuticals Inc. shareholder filed a class action against the company in Massachusetts federal court Monday, alleging it intentionally misled investors about muscular dystrophy drug eteplirsen's chances of hitting the open market.